Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference June 2026

Tenaya Therapeutics to present at Jefferies Global Healthcare Conference on June 4, 2026, highlighting its heart disease therapies.

Quiver AI Summary

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing therapies for heart disease, announced that its executive team will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026, in New York. CEO Faraz Ali will present the company on June 4 at 3:10 p.m. ET, with a live webcast accessible on Tenaya's website and an archived replay available for 30 days post-conference. Tenaya's pipeline includes gene therapies targeting specific heart conditions and a small molecule for broader cardiac and metabolic issues, emphasizing their commitment to addressing the root causes of heart disease through innovative treatments. For more information, visit their website.

Potential Positives

Tenaya Therapeutics is participating in the prestigious Jefferies Global Healthcare Conference, enhancing its visibility and credibility in the biotechnology sector.
The presentation by Chief Executive Officer Faraz Ali provides an opportunity to share the company's innovative pipeline, which includes potentially groundbreaking therapies for significant heart conditions.
Tenaya's commitment to developing curative therapies for heart disease addresses a critical area in healthcare with high unmet needs, potentially attracting investor interest.
The availability of a live webcast and archived replay of the presentation increases accessibility for stakeholders and promotes transparency.

Potential Negatives

None

FAQ

When is the Jefferies Global Healthcare Conference?

The Jefferies Global Healthcare Conference takes place from June 2-4, 2026, in New York, New York.

Who will present at the conference?

Faraz Ali, Tenaya’s Chief Executive Officer, will present on Thursday, June 4, 2026, at 3:10 p.m. ET.

How can I access the live webcast of the presentation?

The live webcast can be accessed from the Investors section of Tenaya’s website during the presentation.

Will the presentation be available later?

An archived replay of the webcast will be available on Tenaya’s website for approximately 30 days following the conference.

What therapies is Tenaya Therapeutics developing?

Tenaya is developing gene therapies for conditions like HCM and ARVC, and a small molecule inhibitor for cardiac conditions.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$TNYA Insider Trading Activity

$TNYA insiders have traded $TNYA stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $TNYA stock by insiders over the last 6 months:

GROUP III GP, LP COLUMN has made 0 purchases and 12 sales selling 9,400,290 shares for an estimated $5,927,198.
FARAZ ALI (Chief Executive Officer) has made 0 purchases and 4 sales selling 18,252 shares for an estimated $12,246.
WHITTEMORE TINGLEY (Chief Medical Officer) has made 0 purchases and 4 sales selling 8,281 shares for an estimated $5,795.
TOMOHIRO HIGA (SVP, Finance) has made 0 purchases and 4 sales selling 4,954 shares for an estimated $3,409.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$TNYA Hedge Fund Activity

We have seen 60 institutional investors add shares of $TNYA stock to their portfolio, and 49 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

COLUMN GROUP LLC removed 9,400,290 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,508,760
EMPERY ASSET MANAGEMENT, LP added 5,414,101 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,852,132
ANSON FUNDS MANAGEMENT LP added 4,152,966 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,954,835
ALYESKA INVESTMENT GROUP, L.P. removed 4,000,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,769,600
VANGUARD GROUP INC added 3,495,251 shares (+69.0%) to their portfolio in Q4 2025, for an estimated $2,486,871
BURKEHILL GLOBAL MANAGEMENT, LP added 2,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,423,000
RENAISSANCE TECHNOLOGIES LLC added 1,862,894 shares (+100.6%) to their portfolio in Q1 2026, for an estimated $1,289,867

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TNYA Analyst Ratings

Wall Street analysts have issued reports on $TNYA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Canaccord Genuity issued a "Buy" rating on 12/18/2025
Chardan Capital issued a "Buy" rating on 12/12/2025
HC Wainwright & Co. issued a "Buy" rating on 12/12/2025

To track analyst ratings and price targets for $TNYA, check out Quiver Quantitative's $TNYA forecast page.

$TNYA Price Targets

Multiple analysts have issued price targets for $TNYA recently. We have seen 3 analysts offer price targets for $TNYA in the last 6 months, with a median target of $5.0.

Here are some recent targets:

Geulah Livshits from Chardan Capital set a target price of $8.0 on 03/12/2026
Whitney Ijem from Canaccord Genuity set a target price of $5.0 on 12/18/2025
Joseph Pantginis from HC Wainwright & Co. set a target price of $3.0 on 12/12/2025

Full Release

SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of its executive team will present and participate in the upcoming Jefferies Global Healthcare Conference taking place from June 2-4, 2026, in New York, New York. Faraz Ali, Tenaya’s Chief Executive Officer, will provide a company presentation on Thursday, June 4, 2026, at 3:10 p.m. ET.

The live webcast of the presentation may be accessed from the Investors section of Tenaya’s website . An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com .

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
[email protected]

Investors
Anne-Marie Fields
Precision AQ
[email protected]